Astrimmune

Implementation and Validation of a novel test for pancreatic and other gastrointestinal cancers based on shed tumour cells in the blood

Funding £1,095,180
Competition Cancer
Competition Date Autumn 2013
Local AHSN East Midlands AHSN
Website http://astrimmune.com/
Key Contact Fred Jacobs
Status On Market

Pathways Cancer
Technology In-vitro Diagnostics

Astrimmune is developing a diagnostic test for pancreatic and other gastrointestinal cancers based on detection and profiling of shed tumour cells in the blood. Requiring only 6ml of blood, the test provides unique insight into surface markers and gene expression of pancreatic cancer cells; isolating these cells from blood allows detection before metastasis can occur. Survival rates of pancreatic cancer could be improved dramatically if early detection were possible.